The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer
BACKGROUND: Biliary tract cancers (BTCs) are known to have a dismal prognosis. A number of chemokines play important roles in the progress of BTCs. However, the serum levels of chemokines in BTCs have not yet been explored. METHODS: The sera of healthy donors (n = 8) and patients with BTCs who were...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-04-01
|
| Series: | Translational Oncology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S193652331730431X |
| _version_ | 1818174588021899264 |
|---|---|
| author | Su Jin Lee Jung Eun Kim Seung Tae Kim Jeeyun Lee Se Hoon Park Joon Oh Park Won Ki Kang Young Suk Park Ho Yeong Lim |
| author_facet | Su Jin Lee Jung Eun Kim Seung Tae Kim Jeeyun Lee Se Hoon Park Joon Oh Park Won Ki Kang Young Suk Park Ho Yeong Lim |
| author_sort | Su Jin Lee |
| collection | DOAJ |
| description | BACKGROUND: Biliary tract cancers (BTCs) are known to have a dismal prognosis. A number of chemokines play important roles in the progress of BTCs. However, the serum levels of chemokines in BTCs have not yet been explored. METHODS: The sera of healthy donors (n = 8) and patients with BTCs who were enrolled in second line sunitinib trials (n = 27) were collected. The concentrations of three kinds of chemokines (CXCL5, CXCL8 and CXCL12) were measured using ELISA assay. The median concentrations of chemokines were compared between healthy donors and BTC patients and the role of chemokines as a prognostic biomarker was examined. RESULTS: BTC patients generally had higher serum levels of CXCL5 and CXCL12 compared to healthy donors. Patients with cholangiocarcinoma showed significantly higher levels of serum CXCL12 than patients with gallbladder cancer. In survival analysis, only CXCL12 level showed a prognostic impact on overall survival (median OS: 6.9 vs. 0.9 months in low CXCL12 vs. high CXCL12, respectively; P = .008). High CXCL5 levels were also correlated with poor survival without statistical insignificance (median OS: 6.2 vs. 2.0 months in low CXCL5 vs. high CXCL5, respectively; P = .070). CONCLUSIONS: There was a significant difference in OS according to the level of CXCL12, suggesting that serum CXCL12 levels may be a useful surrogate marker for clinical outcome in advanced BTCs. |
| first_indexed | 2024-12-11T19:46:47Z |
| format | Article |
| id | doaj.art-ecb99668112a44d29af5d8ba8a3417cf |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-12-11T19:46:47Z |
| publishDate | 2018-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-ecb99668112a44d29af5d8ba8a3417cf2022-12-22T00:52:54ZengElsevierTranslational Oncology1936-52332018-04-01112353357The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract CancerSu Jin Lee0Jung Eun Kim1Seung Tae Kim2Jeeyun Lee3Se Hoon Park4Joon Oh Park5Won Ki Kang6Young Suk Park7Ho Yeong Lim8Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaDivision of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaDivision of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaDivision of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaDivision of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaDivision of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaDivision of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaDivision of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaAddress all correspondence to: Ho Yeong Lim, MD, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea.; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaBACKGROUND: Biliary tract cancers (BTCs) are known to have a dismal prognosis. A number of chemokines play important roles in the progress of BTCs. However, the serum levels of chemokines in BTCs have not yet been explored. METHODS: The sera of healthy donors (n = 8) and patients with BTCs who were enrolled in second line sunitinib trials (n = 27) were collected. The concentrations of three kinds of chemokines (CXCL5, CXCL8 and CXCL12) were measured using ELISA assay. The median concentrations of chemokines were compared between healthy donors and BTC patients and the role of chemokines as a prognostic biomarker was examined. RESULTS: BTC patients generally had higher serum levels of CXCL5 and CXCL12 compared to healthy donors. Patients with cholangiocarcinoma showed significantly higher levels of serum CXCL12 than patients with gallbladder cancer. In survival analysis, only CXCL12 level showed a prognostic impact on overall survival (median OS: 6.9 vs. 0.9 months in low CXCL12 vs. high CXCL12, respectively; P = .008). High CXCL5 levels were also correlated with poor survival without statistical insignificance (median OS: 6.2 vs. 2.0 months in low CXCL5 vs. high CXCL5, respectively; P = .070). CONCLUSIONS: There was a significant difference in OS according to the level of CXCL12, suggesting that serum CXCL12 levels may be a useful surrogate marker for clinical outcome in advanced BTCs.http://www.sciencedirect.com/science/article/pii/S193652331730431X |
| spellingShingle | Su Jin Lee Jung Eun Kim Seung Tae Kim Jeeyun Lee Se Hoon Park Joon Oh Park Won Ki Kang Young Suk Park Ho Yeong Lim The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer Translational Oncology |
| title | The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer |
| title_full | The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer |
| title_fullStr | The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer |
| title_full_unstemmed | The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer |
| title_short | The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer |
| title_sort | correlation between serum chemokines and clinical outcome in patients with advanced biliary tract cancer |
| url | http://www.sciencedirect.com/science/article/pii/S193652331730431X |
| work_keys_str_mv | AT sujinlee thecorrelationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer AT jungeunkim thecorrelationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer AT seungtaekim thecorrelationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer AT jeeyunlee thecorrelationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer AT sehoonpark thecorrelationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer AT joonohpark thecorrelationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer AT wonkikang thecorrelationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer AT youngsukpark thecorrelationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer AT hoyeonglim thecorrelationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer AT sujinlee correlationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer AT jungeunkim correlationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer AT seungtaekim correlationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer AT jeeyunlee correlationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer AT sehoonpark correlationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer AT joonohpark correlationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer AT wonkikang correlationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer AT youngsukpark correlationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer AT hoyeonglim correlationbetweenserumchemokinesandclinicaloutcomeinpatientswithadvancedbiliarytractcancer |